1. <menuitem id="mw5yx"></menuitem>
      1. <tbody id="mw5yx"></tbody>

        <track id="mw5yx"></track>

              <tbody id="mw5yx"></tbody>

                A LONG-TERM FOCUS
                ON INNOVATION

                We welcome the opportunity to discuss:

                BUSINESS
                DEVELOPMENT
                COLLABORATIONS

                • In-licensing and / or R&D collaborations
                  • Creative collaborations in emerging fields
                  • Best-in-class technology platforms and capabilities to enhance the Regeneron antibody pipeline
                • Strategic late-stage development and commercial partnerships with other leading biopharma companies
                • Collaborations that maximize the global potential of our pipeline and ability to deliver new medicines to patients around the globe

                Introduce your assets or discuss
                late-stage partnership

                ACADEMIC &
                RESEARCH
                COLLABORATIONS

                • Non-Clinical Research Collaborations providing investigators from academic and research institutions access to our:

                Learn more

                • Clinical Collaborations / Investigator Initiated Studies (IIS) providing investigators and clinicians access to and / or funding for our:

                Learn more

                OUR BUSINESS DEVELOPMENT STRATEGY

                Our entrepreneurial culture and history as one of the industry’s longest-standing biotech companies fosters a high-science mindset, nimble decision-making and highly collaborative relationships.

                We follow the science, rather than limiting our innovations to any one therapeutic area. We are open to collaboration opportunities with the potential to offer important benefits to patients, representing a true scientific or medical advance. In particular, we consider:

                • Novel platforms that enable next-generation therapeutics
                • Technologies for antibody discovery and development against new / challenging targets
                • New approaches that enhance activity of tumor-directed antibodies
                • Biomarker discovery and validation
                • Drug delivery or formulation technologies that improve the efficacy / safety profile, address a CMC or supply challenge or enhance patient convenience or compliance
                • Studying the potential of combinations pairing our pipeline molecules with other innovative clinical-stage therapeutic candidates
                • Collaborations with leading academic groups to advance our efforts in human genetics, animal model development, target discovery, target validation and antibody discovery

                SOME OF OUR CURRENT COLLABORATORS INCLUDE:


                Bayer logo

                Global ophthalmology
                collaborations

                Sanofi logo

                Antibody and immunotherapy
                collaborations

                Icahn School of Medicine logo

                Antibody discovery
                agreement

                Columbia University logo

                Research collaboration on genetic
                basis of familial disease

                Teva logo

                Global collaboration for
                investigational pain therapeutic

                Intellia Therapeutics logo

                Gene-editing technology
                collaboration

                Adicet Bio logo

                Engineered immune cell
                therapeutics collaboration

                Alnylam logo

                RNA interference (RNAi)
                therapeutics collaboration

                怡红院在线 视频免费